Cargando…
A new-generation of Bacillus subtilis cell factory for further elevated scyllo-inositol production
BACKGROUND: A stereoisomer of inositol, scyllo-inositol (SI), has been regarded as a promising therapeutic agent for Alzheimer’s disease. However, this compound is relatively rare, whereas another stereoisomer of inositol, myo-inositol (MI) is abundant in nature. Bacillus subtilis 168 has the abilit...
Autores principales: | Tanaka, Kosei, Natsume, Ayane, Ishikawa, Shu, Takenaka, Shinji, Yoshida, Ken-ichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5401388/ https://www.ncbi.nlm.nih.gov/pubmed/28431560 http://dx.doi.org/10.1186/s12934-017-0682-0 |
Ejemplares similares
-
An improved Bacillus subtilis cell factory for producing scyllo-inositol, a promising therapeutic agent for Alzheimer’s disease
por: Tanaka, Kosei, et al.
Publicado: (2013) -
A cell factory of Bacillus subtilis engineered for the simple bioconversion of myo-inositol to scyllo-inositol, a potential therapeutic agent for Alzheimer's disease
por: Yamaoka, Masaru, et al.
Publicado: (2011) -
Bacillus subtilis IolQ (DegA) is a transcriptional repressor of iolX encoding NAD(+)-dependent scyllo-inositol dehydrogenase
por: Kang, Dong-Min, et al.
Publicado: (2017) -
A bacterial cell factory converting glucose into scyllo-inositol, a therapeutic agent for Alzheimer’s disease
por: Michon, Christophe, et al.
Publicado: (2020) -
Bacillus subtilis 5′-nucleotidases with various functions and substrate specificities
por: Terakawa, Ayako, et al.
Publicado: (2016)